S tudies involving children with mono genic autoinflammatory disease have provided insights into the regulation of key proinflammatory cytokine pathways and their role in causing systemic and organ-specific inflammation. 1, 2 We studied six patients who presented in early infancy with systemic inflammation and violaceous, scaling lesions of fingers, toes, nose, cheeks, and ears that progressed to acral necrosis in most of the patients and did not respond to therapy. A mixed histologic pattern was observed, consisting of a prominent dermal inflammatory infiltrate with features of leukocytoclastic vasculitis and microthrombotic angiopathy of small dermal vessels. Three of the patients had severe interstitial lung disease.
Although many of the genetically defined autoinflammatory diseases are associated with increased interleukin-1 signaling and have a clinical response to interleukin-1 inhibition, 2 interleukin-1-inhibiting therapy was ineffective in one of the patients. A prominent interferon-response-gene signature in the peripheral blood of this participant suggested interferon dysregulation similar to that seen in other genetically defined inflammatory syndromes, including the Aicardi-Goutières syndrome, 3, 4 an early-onset inflammatory encephalopathy, and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), 5, 6 a proteasome-associated autoinflammatory syndrome with proposed interferon-mediated pathologic features. 7, 8 We detected autosomal dominant mutations in TMEM173, the gene encoding the stimulator of interferon genes (STING), in the six children we assessed, who presented with a clinical syndrome we have called STING-associated vasculopathy with onset in infancy (SAVI).
ME THODS

PATIENTS
Written informed consent was provided for all four living study participants; for three participants, one or both parents provided written informed consent, and the fourth provided written informed consent himself. These patients were enrolled in an ongoing, institutional review board-approved study of the pathogenesis and natural history of their systemic inflammatory disease at the National Institutes of Health.
GENETIC STUDIES
We obtained samples of genomic DNA from Patient 1 and her parents for whole-exome sequencing (performed by Otogenetics and Beijing Genomics Institute). We used Sanger sequencing to analyze the introns and exons of TMEM173, the candidate gene revealed by means of wholeexome sequencing, in five unrelated patients who presented with a clinically similar phenotype.
FUNCTIONAL STUDIES
Quantitative reverse-transcriptase-polymerasechain-reaction, cytokine, protein, and gene-expression analyses were performed according to standard procedures and are described in the Supplementary Appendix, available with the full text of this article at NEJM.org. Constructs of mutated TMEM173 (V147L, N154S, V155M, and V155R) and nonmutated TMEM173 were transfected into a STING-negative cell line (HEK293T cells) and stimulated with the STING ligand cyclic guanosine monophosphate-adenosine monophosphate (cGAMP [3′3′-cGAMP, Invivogen]).
When possible, we obtained blood and tissue samples from the study participants to assess activation and cell death of peripheral-blood cells. Tissue blocks from skin biopsies (in five patients), samples from lung biopsies (in two), and slides of a sample from a previous muscle biopsy (in one) were obtained and analyzed. Dermal fibroblast lines were obtained from two patients, four healthy controls, and three controls with the CANDLE syndrome. Primary endothelial cells were stimulated with the STING ligand cGAMP.
CD4 T cells and CD19 B cells from Patients 4 and 6 were treated for 4 hours with one of three Janus kinase (JAK) inhibitors -tofacitinib (1 μM), ruxolitinib (100 nM), or baricitinib (200 nM) -to assess their ability to block phosphorylation of the signal transducers and activators of transcription 1 (STAT1) and 3 (STAT3). Fibroblasts from Patient 1 and healthy controls were stimulated with 500 ng of cGAMP per milliliter and were also treated with 0.1 or 1.0 μM tofacitinib. We assayed the suppression of the gene encoding interferon-β (IFNB1) and other interferon-induced genes (CXCL10, MX1, and OAS3). Additional details are provided in the Supplementary Appendix.
R ESULT S
CLINICAL PHENOTYPE
Demographic data and details of the clinical presentation of the six participants are provided in Table 1, and Table S1 in the Supplementary Appendix. All the patients were symptomatic within the first 8 weeks of life. Two patients, Patients 1 and 5, presented initially with tachypnea. Between 2 weeks and 6 months of age, telangiectatic, pustular, or blistering rashes (or a combination of these types) developed on the cheeks, nose, fingers, toes, and soles of all the patients (Fig. 1A and 1B, and Fig. S1A through S1E in the Supplementary Appendix), with evidence of systemic inflammation (elevations of the erythrocyte sedimentation rate and C-reactive protein level) (Table S2 in the Supplementary Appendix). Five patients had recurrent low-grade fever flares. Skin lesions, which worsened in cold weather, extended to the pinnae of the ears and scattered sites on the extremities. Eschar and secondary painful crusts covered ulcerated skin lesions (Fig. S1A through S1E in the Supplementary Appendix).
Over time, clinical features of small-vessel damage developed in all the patients, including nailfold capillary tortuosity and capillary-loop loss (in three patients) ( Fig. S1F and Table S1 in the Supplementary Appendix), and telangiectasia of the extremities and hard palate (in all six). Vascular occlusions caused scarring of the ear cartilage and perforation of the nasal septum (Fig. S1A , S1G, S1H, and S1I in the Supplementary Appendix), dystrophic nail changes, resorption of distal phalanges of fingers and toes, and gangrenous digits necessitating surgical amputation (Table 1; and Table S1 and Fig. S1C , S1D, S1J, S1K, and S1L in the Supplementary Appendix).
Samples from biopsies of lesional skin in all the patients revealed marked vascular inflammation limited to capillaries (Fig. 1C, and Fig. S2A through S2L in the Supplementary Appendix). Microthrombotic vascular changes were seen predominantly in biopsy samples from chronic skin lesions. We did not see vasculitis of medium-size or large vessels or deep venous thrombosis. Skin-biopsy samples from four patients showed evidence of IgM deposition in two patients and C3 deposition in scattered vessels with fibrin deposits in three, suggesting the presence of trapped immune complexes (Fig. S2E through S2H in the Supplementary Appendix). Three patients had low-titer autoantibodies that are seen in vasculitis (cytoplasmic and perinuclear antineutrophil cytoplasmic antibodies [c-ANCA and p-ANCA, respectively]) and the antiphospholipid syndrome (anticardiolipin antibodies and antibodies against B 2 -glycoprotein), but these antibodies disappeared over time (Table S1 in the Supplementary Appendix).
Five of the six patients (all except for Patient 4) had evidence of interstitial lung disease, and all had hilar or paratracheal lymphadenopathy as observed on computed tomography of the chest (Fig. 1D) . However, Patients 3, 4, and 6 had no respiratory symptoms. Lung-biopsy samples from Nodules on face, nose, or ears 6
Distal ulcerative lesions with infarcts 6
Manifestations of vascular and tissue damage Nail dystrophy or loss 6
Gangrene of fingers or toes 4
Nasal-septum perforation 4
Pulmonary manifestations
Paratracheal adenopathy 6
Abnormal pulmonary-function test 5
Interstitial lung disease observed on CT 5
Lung fibrosis 3
Low-titer autoantibodies Biologic agent § 6 * The term c-ANCA denotes cytoplasmic antineutrophil antibody, CT computed tomography, DMARD disease-modifying antirheumatic drug, and SAVI stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy. † Measurements for acute-phase reactants included the C-reactive protein level and the erythrocyte sedimentation rate. ‡ Autoantibody titers were only transiently positive (Table S1 in the Supplementary Appendix). § Biologic agents that elicited minimal clinical responses are listed in Table S1 in the Supplementary Appendix. dren died from pulmonary complications and secondary infection. An autopsy performed on Patient 2 showed a widespread vasculopathy of the systemic and pulmonary vasculature (Table  S3 in the Supplementary Appendix).
GENETIC ANALYSIS OF TMEM173 MUTATIONS
We performed whole-exome sequencing on samples from Patient 1 and her parents, and we filtered coding variants against allele frequencies from public and local databases and variants found in her parents' samples. We identified a de novo germline mutation in a coding region of TMEM173, c.461A→G, p.N154S ( Table S4 in the Supplementary Appendix). Sanger sequencing of DNA from Patient 6 showed a variable prevalence of the mutation c.461A→G, p.N154S across different cell types (whole blood, neutrophils, buccal cells, dermal fibroblasts, and keratinocytes), suggesting somatic mosaicism of the mutation (Fig. S4B and S5 in the Supplementary Appendix). Amino acids at positions 154 and 155 were absolutely conserved across the STING orthologues (across a broad range of species) that we aligned (Fig. S6 in the Supplementary Appendix). The amino acid at position 147 was either valine or isoleucine in most of the STING orthologues we aligned, except for the chicken (Gallus gallus), which carries a leucine at amino acid position 147 (Fig. S6 in the Supplementary Appendix).
FUNCTIONAL ANALYSES
Constitutive Activation of the STING-Interferon-β Pathway
TMEM173 encodes the adaptor protein STING, which functions as a homodimer. On binding its ligand, cGAMP, it mediates the production of interferon-β by means of a pathway involving the phosphorylation of TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF-3) (Fig. 3) . 9 The finding that all three mutations are predicted to result in the substitution of amino acid residues close to the STING dimerization site suggested that they might interfere with dimerization, but two recombinant mutant STING proteins (N154S and V155M) each formed a stable dimer (Fig. S7 in the Supplementary Appendix) (we did not carry out this experiment using the third mutation, V147L).
We observed a strong transcriptional interferonresponse-gene signature and elevated levels of interferon-inducible protein 10 (IP-10) and other interferon-induced cytokines in the peripheral whole blood of four of the patients (Fig. 4A , and Table S5 in the Supplementary Appendix), suggesting that their TMEM173 mutations effected a gain of function in STING, leading to overproduction of interferon. We used cGAMP to stimulate STING and then analyzed downstream events in the STING-interferon-β pathway (IRF-3 phosphorylation and transcription of the gene encoding interferon-β [IFNB1]), interferon-induced STAT1 phosphorylation, and interferon-response-gene induction in participants' peripheral-blood mononuclear cells (PBMCs) and fibroblasts.
STING was expressed in T cells, monocytes, natural killer cells, and dermal fibroblasts but was absent in neutrophils and resting B cells (Fig. S8A and S8B in the Supplementary Appendix). Transcription of IFNB1 and the induction of interferon-response genes were maximally upregulated in PBMCs from the patients; exposure to cGAMP brought about no change (Fig. 4B, and  Fig. S8C in the Supplementary Appendix). In contrast, expression of IFNB1 and interferon-response genes in control cells was low at baseline and increased on exposure to cGAMP. Baseline and induced transcription levels of the genes encoding inter feron-α4 (IFNA4), interferon-γ (IFNG), and the proinflammatory cytokine interleukin-1β (IL1B) were similar in patients and controls, whereas transcription of the genes encoding tumor necrosis factor (TNF) and interleukin-6 (IL6) was elevated in unstimulated PBMCs from the patients and was augmented on exposure to cGAMP (Fig. S8C in the Supplementary Appendix).
STAT1 was constitutively phosphorylated in T and B lymphocytes from the three patients tested and could not be further increased with interferon-α stimulation. Phosphorylation of other STATs was also up-regulated either by interferon-β directly 10 or by other induced cytokines (Fig. S9A and S9B in the Supplementary Appendix). In dermal fibroblasts from the patients, basal IFNB1 transcription was not up-regulated (in Patient 1), but a set of IRF-3-dependent genes that were induced by cGAMP in controls was constitutively upregulated in fibroblasts from Patient 1 (Fig. S10A and S10B in the Supplementary Appendix). Fibroblasts from the patients were more responsive to low-dose stimulation with cGAMP with upregulation of IRF-3 phosphorylation (Fig. S10C in the Supplementary Appendix) and IFNB1 transcription than were fibroblasts from healthy controls or from patients with the CANDLE syndrome 6 (Fig. S10D and S10E in the Supplementary Appendix).
Transfection Experiments and Confirmation of Gain of Function
We transfected HEK293T cells that do not express endogenous STING with nonmutant and mutant constructs encoding STING (N154S, V155M, and V147L, and a previously reported loss-of-function mutant, V155R). 11 IFNB1 reporter activity was highly elevated in cells transfected with the three mutant constructs and was barely boosted on stimulation with the STING ligand cGAMP, a finding that was similar to our observations in PBMCs. In contrast, cells transfected with nonmutated TMEM173, TMEM173 with the loss-of-function mutation, or control plasmid had no substantial baseline activation. Cells transfected with nonmutated TMEM173 had a response to cGAMP stimulation in a dose-dependent manner, and the sample expressing the loss-of-function mutant had a minimal response only at the highest cGAMP concentration (Fig. 4C , and 
STING in Vasculitic Lesions and Its Activation in Endothelial Cells
STING was expressed in endothelial cells from biopsy samples of nonlesional skin from healthy adults and lesional skin from patients with SAVI and in commercially available endothelial-cell lines (Fig. S12A , S12B, and S13A in the Supplementary Appendix). It was also expressed in alveolar type 2 pneumocytes, bronchial epithelium, and alveolar macrophages in lung tissue ( STING, an endoplasmic reticulum transmembrane protein, forms homodimers and functions as an adaptor for cytosolic DNA sensing. STING is activated by the binding of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), a second messenger that is synthesized by cyclic GMP-AMP synthase (cGAS), a family member of nucleotidyltransferases that is activated on its recognition and binding of double-stranded DNA (dsDNA). Binding of cGAMP to the STING homodimer activates interferon regulatory factor 3 (IRF-3) through TANK-binding kinase 1 (TBK1) and leads to the induction of interferon-β. In patients with SAVI, constitutively activated STING leads to increased transcription of the type 1 interferon gene, IFNB1, which encodes interferon-β. Binding of inter feron-β to its receptor activates Janus kinases (JAKs), including JAK1 and tyrosine kinase 2 (TYK2), which in turn phosphorylate the receptor. This process allows the binding of the DNA-binding proteins signal transducers and activators of transcription 1 (STAT1) and 2 (STAT2) to the receptor, whereupon they become phosphorylated (P). Phosphorylation allows them to dimerize, and the dimer translocates to the nucleus, where it up-regulates transcription of interferon-response genes, including interferon regulatory factor 7-dependent transcription of type 1 interferon genes. CEACAM1  TLR5  MMP9  FCGR1A  FCGR1B  IL27  IL1RN  EMID1  CCRL2  GCH1  CIQC  CIQB  CD163  IL15  CDKN1A  LGALS9  TYMP  IFI27  SEPT4  AIM2  CARD17  GBP1  PML  CASP1  IRF7  IFI44L  IFI44  HERC6  ISG15  OASL  USP18  RTP4  IFIT5  IFIH1  RSAD2  IFIT3  OAS3  IFIT2  TRIM22  STAT2  IFI6  STAT1  MX1  OAS2  OAS1  IFIT1  DDX58  MX2  EIF2AK2  CCRL2  CD274  LAMP3  ATF3  TNFSF10  ITGB3  SELP  HLA-G  SP100  CXCL11  CXCL10  CCL2  BCL2L1  BBC3  BCL2L11  HLA-DQB1  BBC3  IL32  IFNG  IL8  PTGS2  PTGES  RTDR1  TCF7L2  TLR3  ITGAV  IL18BP  KLRC4-KLRK1  IRF3  KCTD7  CASP8  AUTS2  LARGE , and P6 denote Patients 1, 3, and 6, respectively. The healthy controls included Patient 1's sibling, father, and mother (HC1, HC2, and HC3, respectively), Patient 3's female sibling and mother (HC4 and HC5, respectively), and two persons who were unrelated to the patients (HC6 and HC7). Errors bars indicate the standard error for triplicates in the assay. Asterisks denote P = 0.01 for the comparison between unstimulated samples from patients and unstimulated samples from controls; no significant increase in IFNB1 mRNA levels was seen after cGAMP stimulation in the patients, as compared with controls. Panel C shows cotransfection of HEK293T cells with a TMEM173 construct (2 ng of plasmid DNA), either the nonmutated gene or a gene with a disease-associated mutation (N154S, V155M, or V147L) or loss-of-function mutation (V155R), in addition to an IFNB1 luciferase reporter construct, performed to assess IFNB1 reporter activity with and without cGAMP stimulation. A green fluorescent protein expressing plasmid was also contransfected as control. The reporter activity was normalized to the result of nonmutant construct without cGAMP stimulation. The three constructs carrying the putative disease-causing mutations, but not the nonmutated constructs, constitutively activated IFNB1 transcription, which was further up-regulated with cGAMP stimulation. The cells with the nonmutated construct responded to cGAMP stimulation in a dose-dependent manner, whereas the cells with the loss-of-function mutation V155R had minimal responses only at the highest cGAMP concentrations. The cells with the control transfection did not respond to all tested cGAMP concentrations. I bars indicate standard errors.
The of these markers in the endothelial cells of healthy controls. The endothelial-cell layer in affected vessels was damaged in some areas and was preserved in healthy controls (Fig. 5 , and Fig. S13A in the Supplementary Appendix).
The skin-biopsy samples showed features of substantial cutaneous small-vessel inflammation with leukocytoclasia, which was present at an early stage of life in all the participants, leading to tissue loss on hands and feet (Fig. S1 and S2 in the Supplementary Appendix). Vasculopathic changes without evidence of thrombosis in larger vessels suggested a widespread vasculopathy (Table S3 in the Supplementary Appendix). To explore the effect of STING in endothelial-cell activation, we assessed the transcription profile of cGAMP-stimulated endothelial cells from human umbilical veins. The genes that showed the greatest increase in expression were interferonresponse genes or other genes that mediate inflammation, as well as genes that control apoptosis, cell adhesion, and coagulation pathways ( Fig. S13B and S13C in the Supplementary Appendix). Stimulation of endothelial cells with cGAMP led to increased expression of inducible nitric oxide synthase, E-selectin, and tissue factor and induced endothelial-cell death (Fig. S13D and S13E in the Supplementary Appendix). Spontaneous cell death was also observed in T cells and monocytes from the patients but not in B cells, which lack STING expression (Fig. S14 in the Supplementary Appendix).
Down-Regulation of STING-Interferon-β Pathway with JAK Inhibitors
There are currently no effective therapies for patients with this disease. We performed in vitro experiments to determine whether three JAK inhibitors -tofacitinib, ruxolitinib, and baricitinib -could suppress the expression of STING-induced targets and interferon-response genes. 12, 13 The JAKs are activated by interferon receptors (on binding of interferon to the receptor) and phosphorylate the potent transcription factors STAT1 and STAT2, leading to the expression of interferonresponse genes (Fig. 3) . 14 of fibroblasts from patients and controls that were then maximally activated with cGAMP led to a 30 to 50% reduction in IFNB1 transcription and a 20 to 40% reduction in the transcription of IL6 and IL1B. However, some interferon-response genes were blocked by 60 to 90% in a dosedependent fashion (Fig. S16 in the Supplementary Appendix).
DISCUSSION
We describe a new autoinflammatory syndrome, which is caused by de novo mutations in TMEM173, the gene that encodes the STING pro- 
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tein. Our data suggest that the three STING mutations that we identified confer a gain of function and constitutive activation of STING and hypersensitivity to ligand stimulation, resulting in chronic activation of the STING-interferon pathway. STING is a key adaptor molecule that links the sensing of cytosolic DNA, derived from foreign triggers (i.e., viral and bacterial) or from self, to the production of interferons, 1519 which are potent cytokines with antiviral and antitumor activity. 2022 Recently, the characterization of cyclic GMP-AMP synthase (cGAS) as a DNA sensor, which on binding double-stranded DNA releases the second messenger 2′3′-cGAMP (a highaffinity ligand of STING), has shed light on the mechanism of STING-induced interferon activation by means of TBK1 and IRF-3 phosphorylation. 23, 24 Interferons modulate innate (autoinflammatory) and adaptive (autoimmune) pathologic immune responses in addition to the cell-intrinsic and antiviral effect. 25, 26 Patients with SAVI share clinical, histologic, and functional features with patients who have the proteasome defect-associated autoinflammatory disease CANDLE, 5,6,27,28 the Aicardi-Goutières syndrome, or TREX1-mediated familial chilblain lupus. 29, 30 Patients with these conditions have a vasculopathy early in life, have granulocyte precursors in the inflammatory skin infiltrate, and present with a prominent interferon-response-gene signature in the peripheral blood and with variable B-cell activation ( chronic hepatitis and multiple sclerosis can, in rare cases, result in vasculitis, 31, 32 and interferoninduced endothelial-cell dysfunction has been implicated as a cause of premature vascular damage and atherosclerosis in patients with systemic lupus erythematosus. 33 Nevertheless, the presentation of SAVI as an inflammatory vasculopathy was unexpected. The characteristic early onset and localized involvement of cheeks, ears, nose, and digits distinguish SAVI from other known vasculitis syndromes. 34 These features, antibodies associated with the antiphospholipid syndrome that were initially present at low titers and then disappeared, and the absence of thrombocytopenia also differentiate SAVI from typical presentations of the antiphospholipid syndrome. 35 Stimulation of the STING pathway can activate endothelial cells directly and induces up-regulation of interferon-response genes, apoptosispathway genes, and endothelial-cell death in culture, as well as tissue-factor expression, which is a potent initiator of the coagulation cascade. Our data suggest that STING-induced endothelial-cell dysfunction may instigate an inflammatory and vaso-occlusive process and localize it to the vessels. In fact, the development of gangrene early in infancy in areas with low-flow circulation, such as the fingers, toes, nose, and ears, resembles other vaso-occlusive conditions characterized by activation of intravascular coagulation, including symmetric peripheral gangrene (a rare complication of sepsis), 36 the antiphospholipid syndrome, 37 and levamisole-induced vasculopathy, 38, 39 raising questions about the role of STING-pathway dysregulation in these conditions. Some studies have suggested that STING acts as a gatekeeper by streamlining the interferon signaling triggered by upstream doublestranded DNA sensors, such as cGAS. 15, 40, 41 For example, in a Trex1-deficient mouse model of the Aicardi-Goutières syndrome, the development of disease features depends on STING, 42 which suggests that the production of interferon in patients with the Aicardi-Goutières syndrome may depend on STING. Blocking STING may therefore represent an experimental therapeutic strategy in interferon-mediated diseases other than SAVI. 30 Options for treating patients with SAVI are currently limited, but our study suggests that the blockade of interferon signaling with a JAK inhibitor may offer a therapeutic strategy. We observed that, at the right dose, JAK inhibitors blocked in vitro IFNB1 transcription by 30 to 50% and the induction of interferon-response genes by 60 to 90%, suggesting that JAK inhibition may break a positive feedback loop that fuels continuous interferon signaling. A recently approved clinical protocol for the treatment of patients with SAVI will assess the clinical response to JAK inhibition (ClinicalTrials.gov number, NCT01724580). 
